一分钟看懂
这是一项关于卵巢癌的III 期研究，登记的药物或干预包括Rina-S；Paclitaxel；Topotecan；Pegylated liposomal doxorubicin (PLD)；Gemcitabine，当前状态为招募中。登记地点显示中国长春、长沙、成都、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Rina-S；Paclitaxel；Topotecan；Pegylated liposomal doxorubicin (PLD)；Gemcitabine · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为女性，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Hospital of Jilin University · 长春
- Hunan Cancer Hospital · 长沙
- West China Second University Hospital, Sichuan University · 成都
- Chongqing University Cancer Hospital - Chongqing Cancer Hospital · 重庆
- Sun Yat-Sen Memorial Hospital · 广州
- Sun Yat-Sen University Cancer Center · 广州
- Zhejiang Cancer Hospital · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Shandong First Medical University Affiliated Tumor Hospital · 济南
- Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School) · 南京
- Fudan University Shanghai Cancer Hospital · 上海
- Obstetrics & Gynecology Hospital of Fudan University · 上海
- Liaoning Cancer Hospital · 沈阳
- Shanxi Cancer Hospital · 太原
- Tianjin Medical University Cancer Institute & Hospital · 天津
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- Henan Cancer Hospital · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
- * Participants may be enrolled regardless of FRα expression level.
- * Participants must have received 1 to 4 prior lines of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
- * Participants must have received prior treatment with the following therapies:
- Platinum chemotherapy
- Prior bevacizumab (or biosimilar) treatment is required, if labeled and available as standard of care per institutional guidelines, unless the participant has a documented contraindication or unless the participant is not eligible for treatment with bevacizumab (or biosimilar) due to precautions/intolerance
- Participants with known or suspected deleterious germline or somatic breast cancer gene (BRCA) mutations and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment unless the participant is not eligible for treatment with PARP inhibitor
- * Mirvetuximab soravtansine, if:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07604766；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。